Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults with biopsy proven and serology-confirmed celiac disease on a gluten-free diet for at least 12 months~* measurable serology at screening~* CeD GSRS score of ≥ 2.0 prior to randomization~* experiencing symptoms (ie, diarrhea, abdominal pain, bloating, nausea, or stomachache)~* willing to maintain current diet gluten-free diet throughout the duration of the study.~Exclusion Criteria:~* refractory celiac disease or severe complications of celiac disease (eg, EATL, ulcerative jejunitis, perforation, etc.)~* chronic active GI disease other than celiac disease~* diabetes (Type 1 or 2) or other autoimmune disease that might interfere with the conduct of the study~* hemoglobin value \< 8.5 g/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Larazotide Acetate 0.5 mg (Type: EXPERIMENTAL): larazotide acetate 0.5 mg capsules TID
- Larazotide Acetate 1 mg (Type: EXPERIMENTAL): larazotide acetate 1 mg capsules TID
- Larazotide Acetate 2 mg (Type: EXPERIMENTAL): larazotide acetate 2 mg capsules TID
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsules TID

Based on this trial design, predict the completion outcome and termination type (if applicable).